1887
  1. Home
  2. Eurosurveillance
  3. Volume 24, Issue 30, 25/Jul/2019
  4. Article
Systematic Review Open Access
Like 0
Download

Abstract

Background

People living with HIV (PLHIV) and people in prison are population groups with a potentially high risk and/or prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Aim

We conducted a systematic review in order to find prevalence and incidence estimates in these populations in the European Union/European Economic Area (EU/EEA).

Methods

Original research articles published between January 2005 and February 2017 were retrieved from PubMed and Embase in February 2017.

Results

Fifty-two articles were included, providing 97 estimates of HBV/HCV infection prevalence or incidence. Estimates of HBV infection prevalence ranged between 2.9% and43.4% in PLHIV and 0.0% and 25.2% in people in prison. Estimates of HCV infection prevalence ranged from 2.9% to 43.4% in PLHIV and 0.0% to 25.2% in people in prison. Incidence estimates ranged between 0.0 and 2.5 cases per 100 person-years for HBV infection in PLHIV. No such data was available for people in prison. HCV infection incidence ranged between 0.3 and 0.9 cases per 100 person-years in PLHIV and between 1 and 1.2 cases per 100 person-years in people in prison. Prevalence estimates were generally higher than in the general population, especially for HCV infection and among groups with multiple risk factors.

Conclusions

PLHIV, people in prison and groups with multiple risk factors, have a high prevalence of HBV and HCV and may be at ongoing risk of infection. These groups should be among the populations prioritised and targeted for active case finding and prevention programmes in the EU/EEA.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.30.1800614
2019-07-25
2024-11-08
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.30.1800614
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/30/eurosurv-24-30-2.html?itemId=/content/10.2807/1560-7917.ES.2019.24.30.1800614&mimeType=html&fmt=ahah

References

  1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.  https://doi.org/10.1016/S0140-6736(15)61412-X  PMID: 26231459 
  2. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76.  https://doi.org/10.1016/S2468-1253(16)30181-9  PMID: 28404132 
  3. Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145(14):2873-85.  https://doi.org/10.1017/S0950268817001947  PMID: 28891457 
  4. McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(2) Suppl;S21-9. PMID: 15084064 
  5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38.  https://doi.org/10.1016/j.jhep.2006.05.013  PMID: 16879891 
  6. Memon MI, Memon MA. Hepatitis C: an epidemiological review. J Viral Hepat. 2002;9(2):84-100.  https://doi.org/10.1046/j.1365-2893.2002.00329.x  PMID: 11876790 
  7. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5) Suppl 1;S35-46. PMID: 12407575 
  8. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28(1):112-25.  https://doi.org/10.1093/epirev/mxj009  PMID: 16754644 
  9. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.  https://doi.org/10.1016/S0140-6736(15)61412-X  PMID: 26231459 
  10. European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C testing activities, needs, and priorities in the EU/EEA 2017. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/en/publications-data/hepatitis-b-and-c-testing-activities-needs-and-priorities-eueea
  11. Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg A-S, et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36.  https://doi.org/10.1016/S2468-1253(17)30045-6  PMID: 28397696 
  12. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403.  https://doi.org/10.1016/S2468-1253(18)30056-6  PMID: 29599078 
  13. Easterbrook PJWHO Guidelines Development Group. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65(1) Suppl;S46-66.  https://doi.org/10.1016/j.jhep.2016.08.002  PMID: 27641988 
  14. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48(2):353-67.  https://doi.org/10.1016/j.jhep.2007.11.009  PMID: 18155314 
  15. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003;23(2):125-36.  https://doi.org/10.1055/s-2003-39951  PMID: 12800066 
  16. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-6.  https://doi.org/10.1001/jama.284.4.450  PMID: 10904508 
  17. Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725-39.  https://doi.org/10.1111/add.13877  PMID: 28543749 
  18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prisons and drugs in Europe: the problem and responses. Lisbon: EMCDDA; 2012. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_191812_EN_TDSI12002ENC.pdf
  19. Tsang TH, Horowitz E, Vugia DJ. Transmission of hepatitis C through tattooing in a United States prison. Am J Gastroenterol. 2001;96(4):1304-5.  https://doi.org/10.1111/j.1572-0241.2001.03728.x  PMID: 11316197 
  20. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.  https://doi.org/10.1016/j.jhep.2017.03.021  PMID: 28427875 
  21. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166(9):637-48.  https://doi.org/10.7326/M16-2575  PMID: 28319996 
  22. WHO Regional Office for Europe (WHO/Europe). Action plan for the health sector response to viral hepatitis in the WHO European Region (2017). Copenhagen: WHO/Europe; 2017. Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/357236/Hepatitis-9789289052870-eng.pdf?ua=1
  23. European Centre for Disease Prevention and Control (ECDC). Hepatitis B and C epidemiology in selected population groups in the EU/EEA. Stockholm: ECDC; 2018. Available from: https://ecdc.europa.eu/en/publications-data/hepatitis-b-and-c-epidemiology-selected-population-groups-eueea
  24. European Centre for Disease Prevention and Control (ECDC). Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016. Available from: https://ecdc.europa.eu/en/publications-data/systematic-review-hepatitis-b-and-c-prevalence-eueea
  25. Scottish Intercollegiate Guidelines Network (SIGN). Critical appraisal notes and checklists. Edinburgh: SIGN; 2015. [Accessed 9 July 2017]. Available from: http://www.sign.ac.uk/checklists-and-notes.html
  26. World Health Organization (WHO). Guidelines on Hepatitis B and C testing. Geneva: WHO; 2017. Available from: https://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/
  27. Ruta SM, Matusa RF, Sultana C, Manolescu L, Kozinetz CA, Kline MW, et al. High prevalence of hepatitis B virus markers in Romanian adolescents with human immunodeficiency virus infection. MedGenMed. 2005;7(1):68.  https://doi.org/10.1186/1758-2652-7-1-68  PMID: 16369373 
  28. Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D. Unselected hepatitis C screening of men who have sex with men attending sexual health clinics. J Infect. 2010;60(5):351-3.  https://doi.org/10.1016/j.jinf.2010.01.013  PMID: 20153770 
  29. Marco A, Gallego C, Caylà JA. Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period. PLoS One. 2014;9(2):e90560.  https://doi.org/10.1371/journal.pone.0090560  PMID: 24587394 
  30. Taylor A, Munro A, Allen E, Dunleavy K, Cameron S, Miller L, et al. Low incidence of hepatitis C virus among prisoners in Scotland. Addiction. 2013;108(7):1296-304.  https://doi.org/10.1111/add.12107  PMID: 23297816 
  31. Haussig JM, Nielsen S, Gassowski M, Bremer V, Marcus U, Wenz B, et al. A large proportion of people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in eight German cities. Int J Infect Dis. 2018;66:5-13.  https://doi.org/10.1016/j.ijid.2017.10.008  PMID: 29097248 
  32. Palmateer NE, Goldberg DJ, Munro A, Taylor A, Yeung A, Wallace LA, et al. Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. Addiction. 2018;113(1):80-90.  https://doi.org/10.1111/add.13944  PMID: 28710874 
  33. Sagnelli E, Starnini G, Sagnelli C, Monarca R, Zumbo G, Pontali E, et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci. 2012;16(15):2142-6. PMID: 23280032 
  34. Miglietta A, Quinten C, Lopalco PL, Duffell E. Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014. Euro Surveill. 2018;23(6):1700278.  https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00278  PMID: 29439751 
  35. European Centre for Disease Prevention and Control (ECDC)/European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Thematic report: People who inject drugs. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2014 progress report. Stockholm: ECDC; 2015. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/dublin-declaration-people-who-inject-drugs.pdf
  36. European Centre for Disease Prevention and Control (ECDC). Thematic report: Prisoners. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2014 progress report. Stockholm: ECDC; 2015. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/dublin-declaration-prisoners-2014.pdf
  37. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323-30.  https://doi.org/10.4254/wjh.v7.i21.2323  PMID: 26413221 
  38. Moazen B, Saeedi Moghaddam S, Silbernagl MA, Lotfizadeh M, Bosworth RJ, Alammehrjerdi Z, et al. Prevalence of Drug Injection, Sexual Activity, Tattooing, and Piercing Among Prison Inmates. Epidemiol Rev. 2018;40(1):58-69.  https://doi.org/10.1093/epirev/mxy002  PMID: 29860343 
  39. Wenz B, Nielsen S, Gassowski M, Santos-Hövener C, Cai W, Ross RS, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14). BMC Public Health. 2016;16(1):927.  https://doi.org/10.1186/s12889-016-3545-4  PMID: 27595567 
  40. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797-808.  https://doi.org/10.1016/S1473-3099(15)00485-5  PMID: 26922272 
  41. Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 2015;35(1):65-70.  https://doi.org/10.1111/liv.12639  PMID: 25040895 
  42. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215-24.  https://doi.org/10.1002/hep.26387  PMID: 23504650 
  43. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008;62(4):305-13.  https://doi.org/10.1136/jech.2006.051599  PMID: 18339822 
  44. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089-102.  https://doi.org/10.1016/S0140-6736(16)30466-4  PMID: 27427453 
  45. Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and Viral Hepatitis Among Imprisoned Key Populations. Epidemiol Rev. 2018;40(1):12-26.  https://doi.org/10.1093/epirev/mxy003  PMID: 29688317 
  46. Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy. Clin Infect Dis. 2018;66(9):1360-5.  https://doi.org/10.1093/cid/cix1007  PMID: 29186320 
  47. Bregenzer A, Conen A, Knuchel J, Friedl A, Eigenmann F, Näf M, et al. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. Swiss Med Wkly. 2017;147:w14544. PMID: 29185250 
  48. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, et al. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017;167(5):311-8.  https://doi.org/10.7326/M17-0118  PMID: 28785771 
  49. European Centre for Disease Prevention and Control (ECDC)/European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Prevention and control of infectious diseases among people who inject drugs. Stockholm: ECDC; 2011. Available from: http://www.emcdda.europa.eu/system/files/publications/638/ECDC-EMCDDA_IDU_guidance_-_web_version_328027.pdf
  50. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Harm reduction: evidence, impacts and challenges. Lisbon: EMCDDA; 2010. Available from: http://www.emcdda.europa.eu/system/files/publications/555/EMCDDA-monograph10-harm_reduction_final_205049.pdf
  51. Wiessing L, Ferri M, Běláčková V, Carrieri P, Friedman SR, Folch C, et al. Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduct J. 2017;14(1):19.  https://doi.org/10.1186/s12954-017-0141-6  PMID: 28431584 
  52. Tavoschi L, Vroling H, Madeddu G, Babudieri S, Monarca R, Vonk Noordegraaf-Schouten M, et al. Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area. Epidemiol Rev. 2018;40(1):105-20.  https://doi.org/10.1093/epirev/mxy001  PMID: 29648594 
  53. European Centre for Disease Prevention and Control (ECDC)/European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Public health guidance on active case finding of communicable diseases in prison settings. Stockholm/Lisbon: ECDC/EMCDDA; 2018. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Active-case-finding-communicable-diseases-in-prisons.pdf
  54. He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med. 2016;164(2):84-92.  https://doi.org/10.7326/M15-0617  PMID: 26595252 
  55. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112(7):1302-14.  https://doi.org/10.1111/add.13783  PMID: 28257600 
  56. European AIDS Clinical Society (EACS). EACS Guidelines, Version 9.0. Brussels: EACS; 2017. Available from: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
  57. Raben D, Mocroft A, Rayment M, Mitsura VM, Hadziosmanovic V, Sthoeger ZM, et al. Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. PLoS One. 2015;10(11):e0140845.  https://doi.org/10.1371/journal.pone.0140845  PMID: 26560105 
  58. European Centre for Disease Prevention and Control (ECDC). Public health guidance on HIV, hepatitis B and C testing in the EU/EEA – An integrated approach. Stockholm: ECDC; 2018. Available from: https://ecdc.europa.eu/sites/portal/files/documents/hiv-hep-testing-guidance_0.pdf
  59. Alexiev I, Alexandrova M, Golkocheva-Markova E, Teoharov P, Gancheva A, Kostadinova A, et al. High Rate of Hepatitis B and C Coinfections Among People Living with HIV-1 in Bulgaria: 2010-2014. AIDS Res Hum Retroviruses. 2017;33(3):228-9.  https://doi.org/10.1089/aid.2016.0148  PMID: 27841662 
  60. Andersen KL, Larsen CS, Petersen MS, Leutscher PD. Need for improvements in the surveillance and management of chronic viral hepatitis in HIV patients followed in a Danish outpatient clinic. Scand J Infect Dis. 2014;46(8):578-84.  https://doi.org/10.3109/00365548.2014.918648  PMID: 24934989 
  61. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill. 2008;13(22):18888. PMID: 18761958 
  62. Jansen K, Thamm M, Bock CT, Scheufele R, Kücherer C, Muenstermann D, et al. High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. PLoS One. 2015;10(11):e0142515.  https://doi.org/10.1371/journal.pone.0142515  PMID: 26555244 
  63. Elefsiniotis S, Paparizos V, Botsi C, Pantazis KD, Katsambas A. Serological profile and virological evaluation of hepatitis B and hepatitis C virus infection among HIV infected patients in Greece. Cent Eur J Public Health. 2006;14(1):22-4.  https://doi.org/10.21101/cejph.b0047  PMID: 16705877 
  64. Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS. 2007;21(5):599-606.  https://doi.org/10.1097/QAD.0b013e328013db9c  PMID: 17314522 
  65. Monarca R, Madeddu G, Ranieri R, Carbonara S, Leo G, Sardo M, et al. HIV treatment and care among Italian inmates: a one-month point survey. BMC Infect Dis. 2015;15(1):562.  https://doi.org/10.1186/s12879-015-1301-5  PMID: 26653247 
  66. Sanarico N, D’Amato S, Bruni R, Rovetto C, Salvi E, Di Zeo P, et al. Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study. Medicine (Baltimore). 2016;95(44):e5257.  https://doi.org/10.1097/MD.0000000000005257  PMID: 27858889 
  67. Zhang S, van Sighem A, Kesselring A, Gras L, Prins JM, Hassink E, et al. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy. HIV Med. 2015;16(5):265-72.  https://doi.org/10.1111/hiv.12202  PMID: 25604160 
  68. Pérez Cachafeiro S, Caro-Murillo AM, Berenguer J, Segura F, Gutierrez F, Vidal F, et al. Association of patients’ geographic origins with viral hepatitis co-infection patterns, Spain. Emerg Infect Dis. 2011;17(6):1116-9.  https://doi.org/10.3201/eid/1706.091810  PMID: 21749785 
  69. González-García JJ, Mahillo B, Hernández S, Pacheco R, Diz S, García P, et al. [Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. Enferm Infecc Microbiol Clin. 2005;23(6):340-8. PMID: 15970166 
  70. Berenguer J, Rivero A, Jarrín I, Núñez MJ, Vivancos MJ, Crespo M, et al. Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. Open Forum Infect Dis. 2016;3(2):ofw059.  https://doi.org/10.1093/ofid/ofw059  PMID: 27186584 
  71. Llenas-García J, Rubio R, Hernando A, Fiorante S, Maseda D, Matarranz M, et al. [Clinico-epidemiological characteristics of HIV-positive immigrants: study of 371 cases]. Enferm Infecc Microbiol Clin. 2012;30(8):441-51. PMID: 22365618 
  72. Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, et al. Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. PLoS One. 2012;7(11):e49314.  https://doi.org/10.1371/journal.pone.0049314  PMID: 23145150 
  73. Ghosn J, Deveau C, Goujard C, Garrigue I, Saïchi N, Galimand J, et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex Transm Infect. 2006;82(6):458-60.  https://doi.org/10.1136/sti.2006.021493  PMID: 16923739 
  74. Surah S, Kieran J, O’Dea S, Shiel C, Raffee S, Mulcahy F, et al. Use of the Alcohol Use Disorders Identification Test (AUDIT) to determine the prevalence of alcohol misuse among HIV-infected individuals. Int J STD AIDS. 2013;24(7):517-21.  https://doi.org/10.1177/0956462412473885  PMID: 23970765 
  75. Urbanus AT, Van De Laar TJ, Geskus R, Vanhommerig JW, Van Rooijen MS, Schinkel J, et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. AIDS. 2014;28(5):781-90.  https://doi.org/10.1097/QAD.0000000000000126  PMID: 24832014 
  76. van Rooijen M, Heijman T, de Vrieze N, Urbanus A, Speksnijder A, van Leeuwen P, et al. Earlier Detection of Hepatitis C Virus Infection Through Routine Hepatitis C Virus Antibody Screening of Human Immunodeficiency Virus-Positive Men Who Have Sex With Men Attending A Sexually Transmitted Infection Outpatient Clinic: A Longitudinal Study. Sex Transm Dis. 2016;43(9):560-5.  https://doi.org/10.1097/OLQ.0000000000000497  PMID: 27513382 
  77. Grzeszczuk A, Wandalowicz AD, Jaroszewicz J, Flisiak R. Prevalence and risk factors of HCV/HIV co-infection and HCV genotype distribution in North-Eastern Poland. Hepat Mon. 2015;15(7):e27740.  https://doi.org/10.5812/hepatmon.27740v2  PMID: 26300929 
  78. Škamperle M, Seme K, Lunar MM, Maver PJ, Tomažič J, Vovko TD, et al. Prevalence, genotype distribution, and risk factors for hepatitis C infection among HIV-infected individuals in Slovenia: a 1986-2013 update. Acta Dermatovenerol Alp Panonica Adriat. 2014;23(2):25-6.  https://doi.org/10.15570/actaapa.2014.6  PMID: 24964945 
  79. Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-Villegas MJ, et al. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. Eur J Clin Microbiol Infect Dis. 2015;34(11):2247-55.  https://doi.org/10.1007/s10096-015-2476-9  PMID: 26342330 
  80. Stenkvist J, Weiland O, Sönnerborg A, Blaxhult A, Falconer K. High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. Scand J Infect Dis. 2014;46(9):624-32.  https://doi.org/10.3109/00365548.2014.921932  PMID: 24984040 
  81. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, et al. The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat. 2010;17(8):569-77.  https://doi.org/10.1111/j.1365-2893.2009.01215.x  PMID: 19840365 
  82. Dougan S, Balogun MA, Elford J, Brant LJ, Sinka K, Evans BG, et al. Can current national surveillance systems in England and Wales monitor sexual transmission of hepatitis C among HIV-infected men who have sex with men? BMC Public Health. 2007;7(1):7.  https://doi.org/10.1186/1471-2458-7-7  PMID: 17233919 
  83. Balogun MA, Murphy N, Nunn S, Grant A, Andrews NJ, Teo CG, et al. Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiol Infect. 2009;137(7):980-7.  https://doi.org/10.1017/S0950268808001660  PMID: 19102796 
  84. Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, et al. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis. Infection. 2008;36(1):46-53.  https://doi.org/10.1007/s15010-007-6300-z  PMID: 18231722 
  85. Heuft MM, Houba SM, van den Berk GE, Smissaert van de Haere T, van Dam AP, Dijksman LM, et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;28(7):999-1005.  https://doi.org/10.1097/QAD.0000000000000180  PMID: 24685742 
  86. Apers L, Koole O, Bottieau E, Vandenbruaene M, Ophoff D, Van Esbroeck M, et al. Incidence of HCV and sexually transmitted diseases among hiv positive msm in antwerp, belgium, 2001-2011. Acta Clin Belg. 2013;68(6):421-6.  https://doi.org/10.2143/ACB.3315  PMID: 24635329 
  87. Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill. 2010;15(39):19673. PMID: 20929655 
  88. Barfod TS, Omland LH, Katzenstein TL. Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006-2009): a retrospective cohort study. Scand J Infect Dis. 2011;43(2):145-8.  https://doi.org/10.3109/00365548.2010.524660  PMID: 20923257 
  89. Larsen C, Chaix ML, Le Strat Y, Velter A, Gervais A, Aupérin I, et al. Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study. PLoS One. 2011;6(12):e29322.  https://doi.org/10.1371/journal.pone.0029322  PMID: 22216248 
  90. Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, et al. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017;23(4):267.e1-4.  https://doi.org/10.1016/j.cmi.2016.12.003  PMID: 27956268 
  91. Hullegie SJ, van den Berk GEL, Leyten EMS, Arends JE, Lauw FN, van der Meer JTM, et al. Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014. Clin Microbiol Infect. 2016;22(2):209.e1-3.  https://doi.org/10.1016/j.cmi.2015.10.012  PMID: 26482267 
  92. Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutiérrez F, Blanco JR, Santos I, et al. Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions. PLoS One. 2014;9(12):e116226.  https://doi.org/10.1371/journal.pone.0116226  PMID: 25549224 
  93. Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect. 2008;84(2):111-5.  https://doi.org/10.1136/sti.2007.027334  PMID: 17932125 
  94. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis. 2016;62(9):1072-80.  https://doi.org/10.1093/cid/ciw075  PMID: 26908813 
  95. Turner JM, Rider AT, Imrie J, Copas AJ, Edwards SG, Dodds JP, et al. Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men. Sex Transm Infect. 2006;82(4):298-300.  https://doi.org/10.1136/sti.2005.018366  PMID: 16877578 
  96. Boesecke C, Grint D, Soriano V, Lundgren JD, d’Arminio Monforte A, Mitsura VM, et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? Liver Int. 2015;35(11):2384-91.  https://doi.org/10.1111/liv.12848  PMID: 25875966 
  97. Jacomet C, Guyot-Lénat A, Bonny C, Henquell C, Rude M, Dydymski S, et al. Addressing the challenges of chronic viral infections and addiction in prisons: the PRODEPIST study. Eur J Public Health. 2016;26(1):122-8.  https://doi.org/10.1093/eurpub/ckv183  PMID: 26454876 
  98. Tresó B, Barcsay E, Tarján A, Horváth G, Dencs A, Hettmann A, et al. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. J Urban Health. 2012;89(1):108-16.  https://doi.org/10.1007/s11524-011-9626-x  PMID: 22143408 
  99. Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005;76(3):311-7.  https://doi.org/10.1002/jmv.20375  PMID: 15902712 
  100. Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW. [Risk factors for hepatitis C among injecting drug users in Oslo]. Tidsskr Nor Laegeforen. 2009;129(2):101-4.  https://doi.org/10.4045/tidsskr.09.35002  PMID: 19151801 
  101. Vallejo F, Barrio G, Brugal MT, Pulido J, Toro C, Sordo L, et al. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. J Epidemiol Community Health. 2015;69(6):599-603.  https://doi.org/10.1136/jech-2014-205070  PMID: 25870164 
Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Lauren+MK+Mason&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mason Lauren MK</a>, <a href="/search?value1=Erika+Duffell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duffell Erika</a>, <a href="/search?value1=Irene+K+Veldhuijzen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Veldhuijzen Irene K</a>, <a href="/search?value1=Uarda+Petriti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Petriti Uarda</a>, <a href="/search?value1=Eveline+M+Bunge&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bunge Eveline M</a>, <a href="/search?value1=Lara+Tavoschi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tavoschi Lara</a></span>. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. <a href="/content/ecdc">Euro Surveill.</a> 2019;24(30):pii=1800614. <a href="https://doi.org/10.2807/1560-7917.ES.2019.24.30.1800614" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.30.1800614</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 12 Nov 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 05 Jun 2019 </span> </p>
/content/10.2807/1560-7917.ES.2019.24.30.1800614
/content/10.2807/1560-7917.ES.2019.24.30.1800614
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error